Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Bristol-Myers

Kadmon Hlds

Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.

Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market

Why Protagonist Should Be On Your Radar After Latest Trial Update

The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.

Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide...

Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera

NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual BMO Prescriptions for Success Healthcare Conference....

Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference

Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning

NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25th European Hematology Association (EHA) Annual Congress, which...

Protagonist Therapeutics to Present at the 25th European Hematology Association (EHA) Annual Congress

NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming virtual healthcare investor conferences. Presentation details: Event: Jefferies...

Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript

MacroGenics

Stemline Therapeutics

Here's what's behind their impressive market performances.

3 Small-Cap Biotech Stocks That Surged Last Week

Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.

Why Did Protagonist Therapeutics (PTGX) Soar 83.7% Today?

The company is set to start a pivotal study for one of its lead pipeline candidates.

Why Protagonist Therapeutics Is Skyrocketing Today

Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

Allergan

Alector Inc

Amarin Corporation Plc

Athenex

Biohaven Pharmaceutical Hld

Cara Therapeutics

Global Blood Therapeutics

Intra-Cellular Therapies

Novartis

Puma Biotechnology

Proteostasis Therapeutics

Rocket Pharma

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Biotech’s Year-End To-Do List

Protagonist's Upcoming Catalyst Has The Potential To Carve Out A Solid Path With Lead Drug

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Protagonist Therapeutics (PTGX) Q3 Earnings Expected to Decline

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates

Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline

News for Protagonist Therapeutics Stock (PTGX)